ELABELA Ameliorates Atherosclerosis Through Restoring the M1/M2 Macrophage Balance in <i>ApoE</i> <sup>−/−</sup> Mice
Our data highlighted the diagnostic and therapeutic potential of ELABELA on atherosclerosis. ELA-21 protects against atherosclerosis by inhibiting atherosclerotic plaque formation and promoting a more stable plaque phenotype, possibly via restoring the M1/M2 macrophage balance, enhancing macrophage ACE and ACE2 expression, and inhibiting the PRR system. ELABELA may be a novel diagnostic biomarker and candidate therapeutic target for atherosclerosis.
Authors
- Lixiang Zheng (ORCID: https://orcid.org/0009-0006-9463-6908)
- Chuanming Xu (ORCID: https://orcid.org/0000-0001-7082-2833)
- Mulan Wang
- Huiru Yang (ORCID: https://orcid.org/0000-0002-2886-8499)
- Le Tang (ORCID: https://orcid.org/0000-0002-5192-3329)
- Wenting Tan (ORCID: https://orcid.org/0000-0002-2884-071X)
- Jun Yu (ORCID: https://orcid.org/0000-0003-4530-2179)
- Jianhua Xiong
- Xiaoli Yi (ORCID: https://orcid.org/0000-0002-6104-8687)
- Chunju Liu (ORCID: https://orcid.org/0000-0002-3464-2189)
- Shanshan Song (ORCID: https://orcid.org/0000-0002-7200-5922)
- Mengzhi Zhu
- Yifeng Zhang (ORCID: https://orcid.org/0000-0001-6078-6015)
Institutions
- Jiangxi University of Traditional Chinese Medicine (CN)
- Temple College (US)
- Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine (CN)
- Temple University (US)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1161/jaha.124.041261
- Citations
- 4
- Primary Topic
- Apelin-related biomedical research
- Type
- article
- Field-Weighted Citation Impact
- 5.58